Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-12-14 00:00:00 ET · period of report 2021-12-10 · accession 0001883850-21-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-14 | 2021-12-10+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $664.34 | -2,081 | 29.4K | -7% | -$1.38M |
| D | 2021-12-14 | 2021-12-13 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $662.50 | -116 | 29.3K | -0.4% | -$76.8K |
| D | 2021-12-14 | 2021-12-10 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $555.67 | +1,500 | 31.5K | +5% | +$833.5K |
| D | 2021-12-14 | 2021-12-10 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,500 | 2,500 | -38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-10 | F | D | 1,384 | $664.34 | 30,073 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-11 | F | D | 697 | $664.34 | 29,376 | D | — | — | |
| 3 | Common | Common Stock | 2021-12-13 | S | D | 116 | $662.50 | 29,260 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-10 | M | A | 1,500 | $555.67 | 31,457 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-10 | M | D | 1,500 | $0.00 | 2,500 | D | $555.67 · — to 2025-12-16 | 1,500 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |